Biomarkers and Prognostic Tools

/Biomarkers and Prognostic Tools

PSA Screening Probably Reduces by 50% the Initial Diagnosis of Metastatic Prostate Cancer

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis included only those men who had been diagnosed with advanced prostate cancer at diagnosis, not of early-stage disease that then progressed to metastasis. In this perspective study the authors describe trends in metastatic prostate cancer prior to and [...]

By | December 4th, 2016|advocacy, Biomarkers and Prognostic Tools, USPTF|0 Comments

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate cancer. The test evaluates the genetic makeup of tumor tissue taken from prostate biopsies. The Oncotype DX test has now been validated for adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death. According to a statement issued by Phil Febbo, M.D., the chief medical officer, Genomic Health, [...]

A New Genetic Test To Help You Understand Your Risk For A Prostate Cancer Recurrence

Base on a recently published news release, a prospective study performed and funded by the commercial company GenomeDx Biosciences showed that their new Decipher Cancer Classifier test reclassifies the tumor aggressiveness in men who have had surgery as their primary prostate cancer treatment. According to the company, this newly validated test will improve clinical decision-making following a radical prostatectomy. In this validation study, their Decipher Post-Op test was able to reclassified the tumor aggressiveness in a large number of men based on the genomic risk assessment as compared to our current clinical and pathological risk assessment tools. The company claims [...]

By | September 12th, 2016|Genetic testing, genetics, prognostic tools, Uncategorized|0 Comments

Is Alkaline Phosphatase A Bio-Marker To Predict PSA Decline And Clinical Benefit From Abiraterone Acetate in Bone Metastatic Castration Resistant Prostate Cancer

Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t exist, so a lot of clinical decision-making is based upon the experience and gut feeling of our doctors. This type of decision-making is not adequate in today’s world of multiple treatment options, especially when many of the treatments can foster resistance to other available treatments. [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー